QUANTIFY CARE

Quantify Care Value Proposition

www.quantifycare.co
info@quantifyholdings.com

Background on breast cancer and mammograms

Background on breast cancer

- Breast cancer is one of the biggest healthcare problems for women in the U.S.
- 1 in 8 women will get breast cancer in their lifetimes
- However, early detection dramatically reduces the death and suffering from breast cancer:
  - If detected at stage 1: 98%+ chance of survival after 5 years, with low treatment costs
  - If detected at stage 4: 22% chance of survival after 5 years, with very high treatment costs

Background on mammograms

- Mammograms are the traditional breast cancer screening technology and have been essentially unchanged for 50+ years
- >50% of US women avoid mammograms in spite of insurance coverage, because:
  1. Mammography equipment is large and expensive (up to $500K), and so can only be deployed in intimidating and inconvenient locations like hospitals
  2. Mammograms result in painful compression of the breast
  3. Mammograms have a miss rate of 21% and false positive rate of 13%
  4. Women wait on average 7-14 days for the results, which leads to anxiety
  5. Mammograms produce so many false positive results in women under 50 that some recommendations have eliminated mammograms for women 40-49, and then every other year after age 50 - even though the best protection is "every year beginning at age 40"

Quantify Care's Bexa technology

- Quantify Care's Bexa technology is the first effective innovation in breast cancer early detection in over 50 years – it is FDA cleared, and clinical trials completed with George Washington University
- The device is size of a computer mouse connected to a tablet – not intimidating and highly portable
- Because of its compact size, it can be deployed in clinics, offices, retail locations, etc.
- Bexa exams are painless – only 1 lb. of gentle pressure on the breast (as opposed to painful compression from mammograms)
- Bexa has a miss rate of 11% (vs. 21% for mammograms) based on clinical trials at George Washington University
- It has a false positive rate of 4% with a concurrent ultrasound (vs. 13% for mammograms)
- Requires only 15 minutes to complete an exam, which is performed by a trained Quantify Care ultrasound technician (does not require a doctor), and results are available immediately
- Radiation-free with no side effects: every woman can be screened every year from any age (irrespective of if they are pregnant or have other health issues)
- Bexa technology is effective for all women, including women with dense breast tissue
- FDA cleared (new 510K issued in July 2019), with a dedicated CPT code (0422T)







Technology and Clinical Trial deep-dive

How the technology works

- Unlike mammograms (which use x-rays), Bexa uses a methodology called high-resolution elastography
- Elastography is a methodology to measure the elasticity (i.e., the hardness) of the breast tissue
- The Bexa device has an array of high resolution capacitive sensors that operate based on the principle that abnormal masses in the breast are harder than the surrounding tissue
- So when the capacitive sensor applies pressure to the breast, abnormal masses will produce higher response pressures, which can be used to generate an image of the mass and analyzed for estimates of the size and relative hardness
- If a positive mass is detected by the examiner, a concurrent ultrasound is immediately performed to confirm the presence of the mass which is confirmed in real-time by a teleradiologist
- The combination of Bexa and ultrasound lowers the false positive rate to around 4%

Clinical trials with George Washington University

- Clinical trials were conducted at George Washington University between Aug 2018 and Aug 2019
- The clinical trial involved women between 30 and 78 years old, or whom 145 had true positive masses
- Bexa correctly identified 129 of the 145 true positive masses, indicating a miss rate of 11% (sensitivity of 89%)



Advantages for employers and next steps

Advantages for employers

- Increase participation in breast cancer early detection among employees and family members
- Improve survival rate and reduce suffering through increased participation in early detection
- Reduce the emotional turmoil of false positives and delayed results
- Low cost for screening (flat $200 fee per exam, incl. immediate ultrasound evaluation of discovered masses) – on average, this lowers breast cancer screening costs by ~44%
- Lower healthcare costs over time since earlier detection leads to lower treatment costs – treatment costs for stage 4 breast cancer can be 10-20x the cost at early stages
- Demonstrate your commitment to employees and their family members to help address one of the biggest healthcare, most frustrating, and emotional healthcare problems for women in the U.S.

Next steps

- In terms of deployment, we are happy to deploy at your on-site clinic, or perform exams on an ad-hoc basis in your office
- If on-site is not an option, we can make Quantify Care screening available at a geographically convenient clinic or pop-up location
- We will also provide engagement collateral for your HR team and provide ongoing analytics